Suzhou-based biopharmaceutical R&D company developing non-viral, non-LNP RNA delivery technology for mucosal administration
Suzhou-based biopharmaceutical R&D company developing non-viral, non-LNP RNA delivery technology for mucosal administration. Its MucoRD delivery vector is designed for routes such as inhalation and oral dosing, with programs focused on pulmonary and immune diseases, including inhaled mRNA treatments and vaccines.